Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.

Wada Y, Gonzalez-Sanchez HM, Weinmann-Menke J, Iwata Y, Ajay AK, Meineck M, Kelley VR.

J Am Soc Nephrol. 2019 Jan 8. pii: ASN.2018090901. doi: 10.1681/ASN.2018090901. [Epub ahead of print]

PMID:
30622154
2.

Dysferlinopathy Promotes an Intramuscle Expansion of Macrophages with a Cyto-Destructive Phenotype.

Baek JH, Many GM, Evesson FJ, Kelley VR.

Am J Pathol. 2017 Jun;187(6):1245-1257. doi: 10.1016/j.ajpath.2017.02.011. Epub 2017 Apr 13.

PMID:
28412297
3.

IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease.

Baek JH, Zeng R, Weinmann-Menke J, Valerius MT, Wada Y, Ajay AK, Colonna M, Kelley VR.

J Clin Invest. 2015 Aug 3;125(8):3198-214. doi: 10.1172/JCI81166. Epub 2015 Jun 29.

4.

Colony-stimulating factor-1: a potential biomarker for lupus nephritis.

Menke J, Amann K, Cavagna L, Blettner M, Weinmann A, Schwarting A, Kelley VR.

J Am Soc Nephrol. 2015 Feb;26(2):379-89. doi: 10.1681/ASN.2013121356. Epub 2014 Jul 10.

5.

Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice.

Iwata Y, Boström EA, Menke J, Rabacal WA, Morel L, Wada T, Kelley VR.

J Immunol. 2012 May 1;188(9):4568-80. doi: 10.4049/jimmunol.1102154. Epub 2012 Mar 30.

6.

Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth.

Menke J, Kriegsmann J, Schimanski CC, Schwartz MM, Schwarting A, Kelley VR.

Cancer Res. 2012 Jan 1;72(1):187-200. doi: 10.1158/0008-5472.CAN-11-1232. Epub 2011 Nov 3.

7.

Distinct roles of CSF-1 isoforms in lupus nephritis.

Menke J, Iwata Y, Rabacal WA, Basu R, Stanley ER, Kelley VR.

J Am Soc Nephrol. 2011 Oct;22(10):1821-33. doi: 10.1681/ASN.2011010038. Epub 2011 Sep 1.

8.

Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.

Menke J, Bork T, Kutska B, Byrne KT, Blanfeld M, Relle M, Kelley VR, Schwarting A.

Kidney Int. 2011 Feb;79(4):452-63. doi: 10.1038/ki.2010.438. Epub 2010 Oct 27.

9.

Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis.

Menke J, Rabacal WA, Byrne KT, Iwata Y, Schwartz MM, Stanley ER, Schwarting A, Kelley VR.

J Am Soc Nephrol. 2009 Dec;20(12):2581-92. doi: 10.1681/ASN.2009050499. Epub 2009 Nov 19.

10.

CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice.

Menke J, Iwata Y, Rabacal WA, Basu R, Yeung YG, Humphreys BD, Wada T, Schwarting A, Stanley ER, Kelley VR.

J Clin Invest. 2009 Aug;119(8):2330-42. doi: 10.1172/JCI39087. Epub 2009 Jul 1.

11.

Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice.

Menke J, Hsu MY, Byrne KT, Lucas JA, Rabacal WA, Croker BP, Zong XH, Stanley ER, Kelley VR.

J Immunol. 2008 Nov 15;181(10):7367-79.

12.

Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.

Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR.

J Immunol. 2008 Aug 15;181(4):2513-21.

13.

CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease.

Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR.

J Am Soc Nephrol. 2008 Jun;19(6):1177-89. doi: 10.1681/ASN.2007111179. Epub 2008 Mar 12.

14.

Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.

Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR.

J Immunol. 2007 Dec 1;179(11):7466-77.

15.

Leukocyte-renal epithelial cell interactions regulate lupus nephritis.

Kelley VR.

Semin Nephrol. 2007 Jan;27(1):59-68. Review.

PMID:
17336689
16.

Distinct in vivo roles of colony-stimulating factor-1 isoforms in renal inflammation.

Jang MH, Herber DM, Jiang X, Nandi S, Dai XM, Zeller G, Stanley ER, Kelley VR.

J Immunol. 2006 Sep 15;177(6):4055-63.

17.

Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus.

Zeller GC, Hirahashi J, Schwarting A, Sharpe AH, Kelley VR.

J Am Soc Nephrol. 2006 Jan;17(1):122-30. Epub 2005 Nov 16.

18.

Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.

Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR.

J Am Soc Nephrol. 2005 Nov;16(11):3264-72. Epub 2005 Oct 12.

19.

Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells.

Duffield JS, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, Bonventre JV.

J Clin Invest. 2005 Jul;115(7):1743-55. Epub 2005 Jun 2.

20.
21.

Chemokines: therapeutic targets for autoimmune and inflammatory renal disease.

Kelley VR, Rovin BH.

Springer Semin Immunopathol. 2003 May;24(4):411-21. Review. No abstract available.

PMID:
12778336
22.
24.

Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.

Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A.

Arthritis Rheum. 2002 Nov;46(11):3083-95.

25.

IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis.

Shinozaki M, Hirahashi J, Lebedeva T, Liew FY, Salant DJ, Maron R, Kelley VR.

J Clin Invest. 2002 Apr;109(7):951-60.

26.
27.

Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice.

Kinoshita K, Tesch G, Schwarting A, Maron R, Sharpe AH, Kelley VR.

J Immunol. 2000 Jun 1;164(11):6046-56.

28.

Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice.

Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR.

J Exp Med. 1999 Dec 20;190(12):1813-24.

29.

IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice.

Schwarting A, Tesch G, Kinoshita K, Maron R, Weiner HL, Kelley VR.

J Immunol. 1999 Dec 15;163(12):6884-91.

30.

Application of genetically engineered tubular epithelial cells in kidney disease.

Yokoyama H, Naito T, Wada T, Kelley VR.

Exp Nephrol. 1999 May-Jun;7(3):267-72.

PMID:
10352368
31.

Lupus nephritis: update on pathogenesis and disease mechanisms.

Foster MH, Kelley VR.

Semin Nephrol. 1999 Mar;19(2):173-81. Review.

PMID:
10192250
32.

Fas on renal parenchymal cells does not promote autoimmune nephritis in MRL mice.

Wada T, Schwarting A, Kinoshita K, Naito T, Griffiths RC, Coffman TM, Kelley VR.

Kidney Int. 1999 Mar;55(3):841-51.

33.

Cytokines in the pathogenesis of systemic lupus erythematosus.

Kelley VR, Wüthrich RP.

Semin Nephrol. 1999 Jan;19(1):57-66. Review.

PMID:
9952281
34.

Gene transfer in the kidney.

Kelley VR, Sukhatme VP.

Am J Physiol. 1999 Jan;276(1 Pt 2):F1-9. Review.

PMID:
9887074
35.

Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis.

Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR.

J Clin Invest. 1999 Jan;103(1):73-80.

36.
37.

Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity.

Kim YS, Maslinski W, Zheng XX, Stevens AC, Li XC, Tesch GH, Kelley VR, Strom TB.

J Immunol. 1998 Jun 15;160(12):5742-8.

38.

Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice.

Moore KJ, Wada T, Barbee SD, Kelley VR.

Kidney Int. 1998 Jun;53(6):1631-41.

39.

IFN-gamma limits macrophage expansion in MRL-Fas(lpr) autoimmune interstitial nephritis: a negative regulatory pathway.

Schwarting A, Moore K, Wada T, Tesch G, Yoon HJ, Kelley VR.

J Immunol. 1998 Apr 15;160(8):4074-81.

40.

Systemic autoimmune nephritogenic components induce CSF-1 and TNF-alpha in MRL kidneys.

Wada T, Naito T, Griffiths RC, Coffman TM, Kelley VR.

Kidney Int. 1997 Oct;52(4):934-41.

41.

Application of a gene transfer strategy to identify molecules that incite autoimmune kidney injury.

Kelley VR, Moore KJ.

Exp Nephrol. 1997 Mar-Apr;5(2):144-51. No abstract available.

PMID:
9108997
42.

A gene transfer system establishes interleukin-6 neither promotes nor suppresses renal injury.

Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR.

Am J Physiol. 1996 Sep;271(3 Pt 2):F603-9.

PMID:
8853422
43.

Dysregulated transforming growth factor-beta in neonatal and adult autoimmune MRL-lpr mice.

Kreft B, Yokoyama H, Naito T, Kelley VR.

J Autoimmun. 1996 Aug;9(4):463-72.

PMID:
8864821
44.

Enhanced response of macrophages to CSF-1 in autoimmune mice: a gene transfer strategy.

Moore KJ, Naito T, Martin C, Kelley VR.

J Immunol. 1996 Jul 1;157(1):433-40.

PMID:
8683149
45.

TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease.

Moore KJ, Yeh K, Naito T, Kelley VR.

J Immunol. 1996 Jul 1;157(1):427-32.

PMID:
8683148
46.

Restriction of the TCR repertoire inhibits the development of memory T cells and prevents autoimmunity in lpr mice.

Perkins DL, Listman JA, Marshak-Rothstein A, Kozlow W, Kelley VR, Finn PW, Rimm IJ.

J Immunol. 1996 Jun 15;156(12):4961-8.

PMID:
8648148
47.

Macrophage growth factors introduced into the kidney initiate renal injury.

Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR.

Mol Med. 1996 May;2(3):297-312.

48.
49.

Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study.

Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, Abrams J, Ryan D, Kelley VR.

Transplantation. 1995 Feb 15;59(3):352-6.

PMID:
7871564
50.

Supplemental Content

Loading ...
Support Center